Kjell Öberg

Kjell Öberg, MD, PhD is Professor Emeritus of Endocrine Oncology at Uppsala University Hospital and one of the founding fathers of modern neuroendocrine tumor medicine. Over a career spanning more than four decades, he pioneered the use of somatostatin analogues for functional NET control, established octreotide and lanreotide as cornerstones of NET management, and conducted some of the earliest systematic studies of interferon-alpha as an antiproliferative agent in carcinoid tumors. His contributions have shaped the foundational understanding of NET biology, classification, and biomarker use globally. Dr. Öberg was instrumental in founding the European Neuroendocrine Tumor Society (ENETS) and served as a principal architect of ENETS consensus guidelines for NET diagnosis and treatment across all anatomical sites, which remain among the most widely cited standards worldwide. He established chromogranin A as the benchmark serum biomarker for NETs and authored early studies defining its prognostic and monitoring utility. His laboratory work on NET genomics and gene expression profiling laid groundwork for contemporary molecular classification. A recipient of numerous lifetime achievement awards, Dr. Öberg has published over 550 peer-reviewed papers, trained hundreds of NET specialists across Europe and North America, and continues to serve as an advisor and emeritus faculty to ENETS and major NET research consortia. His legacy is foundational to virtually every aspect of contemporary NET clinical practice.